Literature DB >> 33762236

Health insurance utilisation after ischaemic stroke in Sweden: a retrospective cohort study in a system of universal healthcare and social insurance.

Carl Willers1, Emma Westerlind2, Fredrik Borgström3,4, Mia von Euler5, Katharina S Sunnerhagen2.   

Abstract

BACKGROUND: Stroke is one of the largest single-condition sources of the global burden of non-communicable disease in terms of disability-adjusted life-years and monetary costs, directly as well as indirectly in terms of informal care and productivity loss. The objective was to assess the population afflicted with ischaemic stroke in working age in the context of universal healthcare and social insurance; to estimate the levels of absence from work, the indirect costs related to that and to assess the associated patient characteristics.
METHODS: This was a retrospective register-based study; all individuals registered with an ischaemic stroke during 2008-2011 in seven Swedish regions, covering the largest cities as well as more rural areas, were included. Individual-level data were used to compute net days of sick leave and disability pension, indirect costs due to productivity loss and to perform regression analysis on net absence from work to assess the associated factors. Costs related to productivity loss were estimated using the human capital approach.
RESULTS: Women had significantly fewer net days of sick leave and disability pension than men after multivariable adjustment, and high-income groups had higher levels of sick leave than low-income groups. There were no significant differences for participants regarding educational level, region of birth or civil status. Indirect monetary costs amounted to €17 400 per stroke case during the first year, totalling approximately €169 million in Sweden.
CONCLUSION: The individual's burden of stroke is heavy in terms of morbidity, and the related productivity loss for society is immense. Income-group differences point to a socioeconomic gradient in the utilisation of the Swedish social insurance. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Entities:  

Keywords:  health economics; public health; stroke

Year:  2021        PMID: 33762236      PMCID: PMC7993163          DOI: 10.1136/bmjopen-2020-043826

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


  15 in total

1.  Long-term costs of stroke using 10-year longitudinal data from the North East Melbourne Stroke Incidence Study.

Authors:  Tristan D Gloede; Sarah M Halbach; Amanda G Thrift; Helen M Dewey; Holger Pfaff; Dominique A Cadilhac
Journal:  Stroke       Date:  2014-11       Impact factor: 7.914

2.  Assessment of functional outcome in a national quality register for acute stroke: can simple self-reported items be transformed into the modified Rankin Scale?

Authors:  Marie Eriksson; Peter Appelros; Bo Norrving; Andreas Terént; Birgitta Stegmayr
Journal:  Stroke       Date:  2007-02-22       Impact factor: 7.914

3.  Cost of stroke in the United Kingdom.

Authors:  Omer Saka; Alistair McGuire; Charles Wolfe
Journal:  Age Ageing       Date:  2009-01       Impact factor: 10.668

4.  Cost of stroke in Sweden: an incidence estimate.

Authors:  Ola Ghatnekar; Ulf Persson; Eva-Lotta Glader; Andreas Terént
Journal:  Int J Technol Assess Health Care       Date:  2004       Impact factor: 2.188

5.  Validation of Hospital Performance Measures of Acute Stroke Care Quality. Riksstroke, the Swedish Stroke Register.

Authors:  Anna Söderholm; Birgitta Stegmayr; Eva-Lotta Glader; Kjell Asplund
Journal:  Neuroepidemiology       Date:  2016-03-15       Impact factor: 3.282

Review 6.  Costs of stroke using patient-level data: a critical review of the literature.

Authors:  Ramon Luengo-Fernandez; Alastair M Gray; Peter M Rothwell
Journal:  Stroke       Date:  2008-12-24       Impact factor: 7.914

7.  Derivation and external validation of a case mix model for the standardized reporting of 30-day stroke mortality rates.

Authors:  Benjamin D Bray; James Campbell; Geoffrey C Cloud; Alex Hoffman; Martin James; Pippa J Tyrrell; Charles D A Wolfe; Anthony G Rudd
Journal:  Stroke       Date:  2014-10-07       Impact factor: 7.914

8.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.

Authors:  Gillian D Sanders; Peter J Neumann; Anirban Basu; Dan W Brock; David Feeny; Murray Krahn; Karen M Kuntz; David O Meltzer; Douglas K Owens; Lisa A Prosser; Joshua A Salomon; Mark J Sculpher; Thomas A Trikalinos; Louise B Russell; Joanna E Siegel; Theodore G Ganiats
Journal:  JAMA       Date:  2016-09-13       Impact factor: 56.272

9.  Cost of stroke: a controlled national study evaluating societal effects on patients and their partners.

Authors:  Poul Jennum; Helle K Iversen; Rikke Ibsen; Jakob Kjellberg
Journal:  BMC Health Serv Res       Date:  2015-10-13       Impact factor: 2.655

10.  Relationship between functional disability and costs one and two years post stroke.

Authors:  Ingrid Lekander; Carl Willers; Mia von Euler; Mikael Lilja; Katharina S Sunnerhagen; Hélène Pessah-Rasmussen; Fredrik Borgström
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.